Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs GSK 239512 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 May 2014 Planned End Date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.